Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
14
Frequently Asked Questions
What is Market Cap of Sagimet Biosciences Inc - Ordinary Shares - Series A?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Sagimet Biosciences Inc - Ordinary Shares - Series A market cap is $231.23M.
What is the 52-week high for Sagimet Biosciences Inc - Ordinary Shares - Series A?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Sagimet Biosciences Inc - Ordinary Shares - Series A 52 week high is $11.41 as of September 06, 2025.
What is the 52-week low for Sagimet Biosciences Inc - Ordinary Shares - Series A?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Sagimet Biosciences Inc - Ordinary Shares - Series A 52 week low is $1.73 as of September 06, 2025.
What is Sagimet Biosciences Inc - Ordinary Shares - Series A stock price today?
Sagimet Biosciences Inc - Ordinary Shares - Series A stock price today is $7.11.
What was Sagimet Biosciences Inc - Ordinary Shares - Series A stock price yesterday?
Sagimet Biosciences Inc - Ordinary Shares - Series A stock price yesterday was $7.25.
What is the PE ratio of Sagimet Biosciences Inc - Ordinary Shares - Series A?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Sagimet Biosciences Inc - Ordinary Shares - Series A’s P/E ratio is -3.85.
What is the Price-to-Book ratio of Sagimet Biosciences Inc - Ordinary Shares - Series A?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Sagimet Biosciences Inc - Ordinary Shares - Series A P/B ratio is 1.7587.
What is the 50-day moving average of Sagimet Biosciences Inc - Ordinary Shares - Series A?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Sagimet Biosciences Inc - Ordinary Shares - Series A 50-day moving average is $8.55.
How many employess does Sagimet Biosciences Inc - Ordinary Shares - Series A has?
Sagimet Biosciences Inc - Ordinary Shares - Series A has 14 employees.
